Literature DB >> 15554999

Videocapsule endoscopy versus barium contrast studies for the diagnosis of Crohn's disease recurrence involving the small intestine.

Alan L Buchman1, Frank H Miller, Anita Wallin, Aqeel A Chowdhry, Chul Ahn.   

Abstract

OBJECTIVES: Historically, suspected Crohn's disease (CD) has been evaluated with small bowel follow-through (SBFT) or enteroclysis (equally accurate). This study was undertaken to determine the accuracy of videocapsule endoscopy (VCE) in the diagnosis of CD relative to SBFT and clinical/laboratory indices of CD activity. Previous investigations have used VCE for the diagnosis of suspected CD in patients presenting with a variety of gastrointestinal symptoms. This is the first study to evaluate the occurrence of active disease in patients with known CD.
METHODS: Thirty subjects (22 female, 8 male, aged 36.9 +/- 14.2 yr); all with prior CD diagnosis made on the basis of standard criteria (5.5 +/- 6.5 yr prior to study), in whom recurrent CD was suspected based on abdominal pain, diarrhea, anemia, and/or arthralgias. Subjects were studied in a prospective, blinded evaluation of VCE versus SBFT. SBFT was performed first; those with stricture and proximal bowel dilation were excluded from further study. For SBFT, studies were graded as grade 0 (normal), grade 1 (minimal nodularity, ulcerations, normal luminal diameter, < 5 cm involved), grade 2 (more extensive ulcers, minimal luminal narrowing, 5-10 cm involved), or grade 3 (fistula, skip areas, extensive ulceration, >10 cm involved). VCE was performed within 1 wk of SBFT. Serum was obtained for ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein), stool was obtained for alpha-1 antitrypsin, and the Harvey Bradshaw index of CD severity was calculated. VCE (digitalized video) was graded as grade 0 (normal), grade 1 (erythema, isolated villi loss), grade 2 (erosion, no ulcer), or grade 3 (ulcers, spontaneous bleeding, and/or stricture).
RESULTS: Twelve patients were excluded for small bowel obstruction. VCE and SBFT scores highly correlated (r = 0.65; p= 0.001). Active CD was visualized in 21 of 30 patients with videocapsule endoscopy and in 20 of 30 patients with SBFT. Complete agreement occurred in 13 of 30 studies; 13 of 17 studies differed by one grade. SBFT found mucosal disease in 20 of 30 patients and VCE found mucosal disease in 21 of 30 patients. VCE found mucosal disease in 6 patients (5 in grade 1, 1 in grade 3) with normal SBFT. SBFT showed CD in 5 patients (all grade 1) with normal VCE. Neither VCE nor SBFT scores correlated with biological or clinical indices. Patient satisfaction was superior for VCE.
CONCLUSIONS: VCE and SBFT are complementary for the diagnosis of CD. SBFT may be required to detect strictures as the videocapsule may not pass. However, some strictures may also be missed with SBFT. VCE is less invasive, less time-consuming for the patient than SBFT, and avoids radiation exposure, although reading time is greater for the gastroenterologist than the radiologist. Given that patients with clinically suspected CD recurrence may not have active disease, unnecessary and potentially harmful empiric therapy is not warranted without imaging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554999     DOI: 10.1111/j.1572-0241.2004.40253.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  28 in total

1.  Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease.

Authors:  Carmelina Petruzziello; Sara Onali; Emma Calabrese; Francesca Zorzi; Marta Ascolani; Giovanna Condino; Elisabetta Lolli; Paola Naccarato; Francesco Pallone; Livia Biancone
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

Review 2.  Patency and Agile capsules.

Authors:  Angel Caunedo-Alvarez; Javier Romero-Vazquez; Juan-M Herrerias-Gutierrez
Journal:  World J Gastroenterol       Date:  2008-09-14       Impact factor: 5.742

3.  Isolated Jejunal Crohn's Disease in an Adolescent Girl.

Authors:  B Bhaskar Raju; Sumathi Bavanandam; Anand Thiagarajan; Nandhini Ganapathy
Journal:  Indian J Pediatr       Date:  2015-05-31       Impact factor: 1.967

Review 4.  Guidelines for video capsule endoscopy: emphasis on Crohn's disease.

Authors:  Soo-Kyung Park; Byong Duk Ye; Kyeong Ok Kim; Cheol Hee Park; Wan-Sik Lee; Byung Ik Jang; Yoon Tae Jeen; Myung-Gyu Choi; Hyun Jung Kim
Journal:  Clin Endosc       Date:  2015-03-27

5.  Recent advances of endoscopy in inflammatory bowel diseases.

Authors:  Jae Hee Cheon; Won Ho Kim
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

6.  Results of videocapsule endoscopy in 250 patients with suspected small bowel pathology.

Authors:  S A C Van Tuyl; J Tenthof Van Noorden; E J Kuipers; M F J Stolk
Journal:  Dig Dis Sci       Date:  2006-06-14       Impact factor: 3.199

7.  Feasibility of small bowel capsule endoscopy in children under the age of 4 years: a single centre experience.

Authors:  Babu Vadamalayan; Michael Hii; Justin Kark; Ingvar Bjarnason
Journal:  Frontline Gastroenterol       Date:  2012-08-11

Review 8.  Current role of capsule endoscopy in Crohn's disease.

Authors:  Marisol Luján-Sanchis; Laura Sanchis-Artero; Laura Larrey-Ruiz; Laura Peño-Muñoz; Paola Núñez-Martínez; Génesis Castillo-López; Lara González-González; Carlos Boix Clemente; Cecilia Albert Antequera; Ana Durá-Ayet; Javier Sempere-Garcia-Argüelles
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

9.  Capsule endoscopy in suspected small bowel Crohn's disease: economic impact of disease diagnosis and treatment.

Authors:  Jonathan A Leighton; Ian M Gralnek; Randel E Richner; Michael J Lacey; Frank J Papatheofanis
Journal:  World J Gastroenterol       Date:  2009-12-07       Impact factor: 5.742

10.  Double-balloon enteroscopy in Crohn's disease patients suspected of small bowel activity: findings and clinical impact.

Authors:  P B F Mensink; M J Groenen; H R van Buuren; E J Kuipers; C J van der Woude
Journal:  J Gastroenterol       Date:  2009-03-07       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.